HubSpot is rebranding its flagship Inbound conference to Unbound as the company pivots to AI after a steep stock slide. The change is part of a broader product and pricing shift.

U.S. News' 2026 research rankings left Massachusetts without a Tier 1 medical school; Tufts and UMass Chan were the state's highest‑ranked programs in Tier 2.

Korsana will take Cyclerion’s Nasdaq listing through an all‑stock reverse merger backed by about $380M, giving the startup cash into 2029 and a faster route to 2027 readouts. The combined company will trade as KRSA.

Eli Lilly will buy Boston‑based Centessa for about $6.3B, adding an orexin agonist program led by cleminorexton. The deal pays $38 per ADS up front and could reach $47 with milestones.

A $280 million renewal from the Stanley Family Foundation brings its Broad Institute giving past $1 billion and backs genetics and translational work on bipolar and schizophrenia.

Biogen agreed to buy Apellis for about $5.6B, paying $41 a share to add pegcetacoplan programs and expand into rare kidney disease treatments.

Fenway-based Whoop raised $575M at roughly a $10B valuation, fueling a 600-job expansion and renewed IPO talk. The funding brings strategic investors and new runway.

Waltham‑based Kailera Therapeutics filed for an IPO on March 30, 2026 after raising nearly $1 billion and advancing an oral and injectable GLP‑1 obesity pipeline.

A federal patent board sided with the Broad Institute on March 27, 2026, preserving key U.S. CRISPR patents and complicating licensing and appeals.

Clasp raised $20 million and will double its Boston staff to scale an employer-sponsored loan-repayment hiring model. The round backs a hiring push across product and partnerships.

Mayor Michelle Wu will unveil a public‑private partnership at Eliot Upper School aimed at making Boston Public Schools a national leader in K‑12 AI literacy. The plan emphasizes classroom curriculum, teacher training and private‑sector support.

Cambridge Mobile Telematics raised $350M from TPG, Allianz and State Farm to expand in Europe and scale AI crash-detection while adding engineering roles in Cambridge.

Pfizer and Valneva say their VLA15 Lyme vaccine is showing promise in late‑stage trials; a Phase 3 readout is expected in early 2026.